Sanjeevan Drugs Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.21 M
- Company Age 24 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.00 M
- Revenue Growth -11.39%
- Profit Growth 441.32%
- Ebitda 76.33%
- Net Worth 2.82%
- Total Assets 21.10%
About Sanjeevan Drugs
Sanjeevan Drugs Private Limited (SDPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 August 2000 and has a history of 24 years and five months. Its registered office is in New Delhi, Delhi, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.21 M.
The company currently has active open charges totaling ₹4.00 M.
Anita Aggarwal and Meghna Singhania serve as directors at the Company.
Company Details
-
Location
New Delhi, Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U33119DL2000PTC107325
-
Company No.
107325
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
17 Aug 2000
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Sanjeevan Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anita Aggarwal
|
Director | 17-Aug-2000 | Current |
|
Meghna Singhania
|
Director | 02-May-2011 | Current |
Financial Performance of Sanjeevan Drugs.
Sanjeevan Drugs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 11.39% decrease. The company also saw a substantial improvement in profitability, with a 441.32% increase in profit. The company's net worth moved up by a moderate rise of 2.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sanjeevan Drugs?
In 2023, Sanjeevan Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Everything Medical Private LimitedMeghna Singhania is a mutual person
-
Minerva Medical Treatment Private LimitedAnita Aggarwal and Meghna Singhania are mutual person
-
Sanjeevan Medical Research Centre Private LimitedAnita Aggarwal is a mutual person
-
Didua Analytics Private Limited
Meghna Singhania is a mutual person
Charges (Loans)
₹4.00 M
₹0
Charges Breakdown by Lending Institutions
- Allahbad Bank : 0.40 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Sep 2011 | Allahbad Bank | ₹4.00 M | Open |
How Many Employees Work at Sanjeevan Drugs?
Unlock and access historical data on people associated with Sanjeevan Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sanjeevan Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sanjeevan Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
